Teemu Niiranen
MD, PhD
tejuni@utu.fi |
Cardiovascular epidemiology; cohort studies; blood pressure; hypertension; blood pressure measurement
Teemu Niiranen, MD, PhD, is a physician-scientist and a clinical hypertension specialist with a track record of productivity in hypertension research, successful mentoring, international research grant procurement, and inter-institutional international collaborations. His research on hypertension in large population cohorts has led to >250 publications that are cited by the European, American, British, and Japanese clinical hypertension guidelines. These publications include first- or last-author articles in BMJ, Circulation, European Heart Journal, Nature Communications and JAMA Cardiology.
After finishing his PhD and clinical training, Dr. Niiranen received in-depth training in cardiovascular disease epidemiology and omics during a post-doctoral period at the Framingham Heart Study, the oldest and most prestigious cardiovascular cohort study in the world. After his post-doctoral period, he was selected as one of the new Group Leaders of the University of Turku Collegium of Science and Medicine and in 2020, the professor of internal medicine at the university. He is also employed as a Medical Specialist by the National Institute for Health and Welfare and chairs the work of the Cardiometabolic Clinical Expert Group of the FinnGen study, a project that has genotyped up to 500 000 unique Finnish blood samples and merged this genetic data with nationwide healthcare registers.
Dr. Niiranen has received young investigator awards from the American and Finnish Societies of Hypertension, and the American Heart Association. He is the past chair of the Finnish Hypertension Society and has mentored 12 PhD students. He is a co-author of the Finnish and European Society of Hypertension clinical hypertension guidelines.
In addition to general cardiovascular epidemiology, Dr. Niiranen's research has focused on the epidemiology of hypertension in large scale population cohorts. His studies particularly focused on home monitoring of blood pressure and more recently he has moved into examining the relation between hypertension and omics (genome, metagenome and metabolome).
Hypertension and clinical epidemioogy.
- Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (vol 611, pg 115, 2022) (2022)
- Nature
- (2022)
- Journal of the American Heart Association
- Risk of sudden cardiac death associated with QRS, QTc, and JTc intervals in the general population (2022)
- Heart Rhythm
- (2022)
- HypertensionAmerican Journal of Hypertension
- (2022)
- Frontiers in Cardiovascular MedicineBlood Pressure Monitoring
- (2022)
- Circulation ResearchBMC Endocrine Disorders
- (2022)
- NatureDuodecim
- Substantial Fat Loss in Physique Competitors Is Characterized by Increased Levels of Bile Acids, Very-Long Chain Fatty Acids, and Oxylipins (2022)
- Metabolites
- Suomalaisten suolistomikrobiston koostumus on yhteydessä tyypin 2 diabeteksen riskiin (2022)
- Diabetes ja lääkäriJournal of Hypertension
- (2022)
- ESC Heart FailureHypertension
- The International Database of Central Arterial Properties for Risk Stratification: Research Objectives and Baseline Characteristics of Participants (2022)
- Translating GWAS data into cardiovascular disease prevention - the Finnish experience (2022)
- Use of antibiotics and risk of type 2 diabetes, overweight and obesity: the Cardiovascular Risk in Young Finns Study and the national FINRISK study (2022)
- Variability independent of mean blood pressure as a real-world measure of cardiovascular risk (2022)
- EClinicalMedicine
- Verenpainetaudin geneettinen tausta (2022)
- Verenpainetauti: edelleen yksi tärkeimmistä kansanterveyden uhkista (2022)
- Duodecim
- 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement (2021)
- Age of Hypertension Onset: Potential for Improving Risk Estimation and Hypertension Management? (2021)
- Age-specific atrial fibrillation incidence, attributable risk factors and risk of stroke and mortality: results from the MORGAM Consortium (2021)
- Open Heart
- Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes (2021)
- European Heart Journal



